作者
Mohammad Saeid Rezaee‐Zavareh,Yee Hui Yeo,Tielong Wang,Zhiyong Guo,Parissa Tabrizian,Stephen C. Ward,Fatma Barakat,Tarek Hassanein,Dave Shravan,Ajmera Veeral,Sherrie Bhoori,Vincenzo Mazzaferro,David M. Chascsa,Margaret C. Liu,Elizabeth S. Aby,John R. Lake,Miguel Sogbe,Bruno Sangro,Maen Abdelrahim,Abdullah Esmail,Andreas Schmiderer,Yasmina Chouik,Mark Rudolph,Davendra Sohal,Héloïse Giudicelli,Manon Allaire,Mehmet Akce,Jessica Guadagno,Clara Tow,Hatef Massoumi,Paolo De Simone,Elise Kang,Robyn D. Gartrell,Mercedes Martínez,Ricardo Paz‐Fumagalli,Beau B. Toskich,Nguyen H. Tran,Gabriela Azevedo Solino,Mariana Poltronieri Pacheco,Richard Kalman,Vatche G. Agopian,Neil Mehta,Neehar D. Parikh,Amit G. Singal,Ju Dong Yang
摘要
Treatment with immune checkpoint inhibitors (ICIs) for hepatocellular carcinoma (HCC) prior to liver transplantation (LT) has been reported; however, ICIs may elevate the risk of allograft rejection and impact other clinical outcomes. This study aims to summarize the impact of ICI use on post-LT outcomes.
eve
蜉蝣
坚强的广山
嗯哼
HEIKU
sswbzh
AireenBeryl531
morena
aaaaaa
加湿器
鼻揩了转去
西红柿炒番茄
tuanheqi
FIN
Marciu33
lynn
三叔
remember
jyy
zho
皖公网安备34019202002308
